Sylvia Andrzejewski is a seasoned scientist with extensive experience in metabolic disease research and drug development. Currently serving as Senior Scientist II/Program Lead at Novo Nordisk since September 2024, Sylvia is leading an internal T2D and obesity program focused on high-throughput small molecule screening and supporting in vivo pharmacology for external partnerships. Previously, as Associate Director at Cellarity from February 2022 to September 2024, Sylvia led a team in developing in vitro phenotypic screening assays and utilizing AI/ML technology to explore novel biology in metabolic diseases. Prior roles include leading metabolic programs at Astellas Pharma and conducting research at McGill and McMaster Universities. Sylvia holds a Ph.D. in Biochemistry from McGill University and a B.Sc. in Biochemistry and Biotechnology from McMaster University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices